What a $722,000 TransMedics Insider Sale Might Mean After a 45% Stock Drop

TransMedics Group director Thomas J. Gunderson sold 9,624 shares worth approximately $722,000 following the exercise of vested stock options to cover exercise costs and tax obligations. The sale reflects routine portfolio management rather than a loss of confidence. Despite a 45% stock decline over the past year, TransMedics reported strong Q1 revenue of $173.9 million (up 21% YoY) and maintained full-year guidance of $727-$757 million, suggesting the stock decline may have been an overreaction.